{"id":20634,"date":"2012-12-01T10:45:10","date_gmt":"2012-12-01T10:45:10","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=20634"},"modified":"2012-12-07T08:31:11","modified_gmt":"2012-12-07T08:31:11","slug":"darunavir-800-mg-tablet-approved-in-the-us","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/20634","title":{"rendered":"Darunavir 800 mg tablet approved in the US"},"content":{"rendered":"<p><strong>On 9 November 2012, the FDA approved an 800 mg tablet of darunavir (Prezista).<\/strong><\/p>\n<p>The Dosage and Administration section of the product label has been changed to:<\/p>\n<p>Treatment-na\u00efve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet or two 400 mg tablets) taken with ritonavir 100 mg once daily and with food.<\/p>\n<p>Source: FDA announcement (9 November 2012)<br \/>\n<a href=\"http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm328097.htm\">http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm328097.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 9 November 2012, the FDA approved an 800 mg tablet of darunavir (Prezista). The Dosage and Administration section of the product label has been changed to: Treatment-na\u00efve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-20634","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=20634"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20634\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=20634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=20634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=20634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}